Biosimilar CT-P13 matches infliximab in improving ankylosing spondylitis disease activity

First Page		Document Content
Date: 2014-12-03 20:00:01 Ankylosing spondylitis BASDAI Infliximab Biologic BASFI Spondylitis Arthritis Rheumatism Medicine Rheumatology Health		Biosimilar CT-P13 matches infliximab in improving ankylosing spondylitis disease activity Add to Reading List Source URL: medicalxpress.com Download Document from Source Website File Size: 20,03 KB Share Document on Facebook

	EAP Reimbursement Criteria for Frequently Requested Drugs DocID: 1rhhE - View Document
	TABLE OF CONTENTS INTRODUCTION 2 DocID: 1qY7G - View Document
	JUNE 2015 TABLE OF CONTENTS INTRODUCTION DocID: 1qDC6 - View Document
	Provincial Drug Programs P. O. Box 2000 Charlottetown PE C1A 7N8Toll Free on PEI) Programmes provinciaux de médicaments DocID: 1qAvE - View Document
	TABLE OF CONTENTS INTRODUCTION 2 DocID: 1qs3R - View Document